Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Coherus Oncology (CHRS) over the last 13 years, with Q3 2025 value amounting to $17.5 million.

  • Coherus Oncology's Other Non-Current Liabilities fell 3983.4% to $17.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.5 million, marking a year-over-year decrease of 3983.4%. This contributed to the annual value of $29.3 million for FY2024, which is 13349.26% up from last year.
  • Coherus Oncology's Other Non-Current Liabilities amounted to $17.5 million in Q3 2025, which was down 3983.4% from $16.7 million recorded in Q2 2025.
  • In the past 5 years, Coherus Oncology's Other Non-Current Liabilities ranged from a high of $31.3 million in Q1 2025 and a low of $102000.0 during Q1 2022
  • In the last 5 years, Coherus Oncology's Other Non-Current Liabilities had a median value of $2.7 million in 2024 and averaged $9.3 million.
  • In the last 5 years, Coherus Oncology's Other Non-Current Liabilities crashed by 8641.81% in 2022 and then surged by 2705392.16% in 2024.
  • Over the past 5 years, Coherus Oncology's Other Non-Current Liabilities (Quarter) stood at $750000.0 in 2021, then surged by 362.27% to $3.5 million in 2022, then surged by 262.3% to $12.6 million in 2023, then soared by 133.49% to $29.3 million in 2024, then crashed by 40.18% to $17.5 million in 2025.
  • Its last three reported values are $17.5 million in Q3 2025, $16.7 million for Q2 2025, and $31.3 million during Q1 2025.